Skip to main content

Advertisement

Table 2 Demographics for the discovery cohort for proteomics analysis

From: A novel workflow combining plaque imaging, plaque and plasma proteomics identifies biomarkers of human coronary atherosclerotic plaque disruption

  Plaque disruption No plaque disruption
Number (male) 10 (7) 10 (5)
Age [years (SD)] 66 (8) 67 (12)
Acute coronary syndrome [n (%)] 5 (50) 6 (60)
Smoking status [n (%)]
 Current smoker 1 (10) 1 (10)
 Past history of smoking (>1 month) 7 (70) 4 (40)
 Never smoked 2 (20) 5 (50)
Past History of IHD [n (%)]
 MI/ACS 2 (20) 5 (50)
 Stable angina 4 (40) 0 (0)
Hypertension [n (%)] 6 (60) 8 (80)
Hypercholesterolemia [n (%)] 8 (80) 6 (60)
Diabetes mellitus [n (%)] 0 (0) 0 (0)
Family history of IHD [n (%)] 6 (60) 5 (50)
Regular medication [n (%)]
 Aspirin 6 (60) 8 (80)
 Thienopyridine 3 (30) 4 (30)
 Statin 7 (70) 9 (70)
 β-blocker 5 (50) 6 (50)
 ACE inhibitor/ARB 6 (60) 7 (60)
Plasma lipid profile
 Total cholesterol [mmol/L (SD)] 3.7 (0.4) 3.8 (1.39)
 HDL [mmol/L (SD)] 1.0 (0.3) 0.9 (0.3)
 LDL [mmol/L (SD)] 2.0 (0.3) 2.3 (1.0)
 Triglyceride [mmol/L (SD)] 1.5 (0.7) 1.5 (0.6)